BioCryst Pharmaceuticals 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Date of Report: July 1, 2005
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive, Birmingham, Alabama 35244
Item 8.01 Other Events.
BioCryst is providing an update on the status of its influenza neuraminidase inhibitor, peramivir. BioCryst possesses exclusive rights to peramivir and maintains the patents covering the compound. BioCryst announced in June 2002 it was discontinuing development of peramivir following a Phase III clinical trial that yielded results that were not statistically significant. Given international health concerns regarding avian flu, the Company has explored possible additional development of the drug candidate. Peramivir has shown activity against avian (bird) flu in cell culture and in animals in pre-clinical testing. The Company is considering various options for the development of peramivir, including whether to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to conduct clinical trials in humans for avian and other viral strains of influenza. BioCryst intends to announce when appropriate its decision on possible future development of peramivir.
Neither the filing of this Current Report on Form 8-K nor the inclusion in such 8-K of a reference to Registrants Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrants Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.